Sun Pharma is preparing to approach the Reserve Bank of India for an exemption under foreign remittance regulations as it moves forward with the Organon acquisition. This article explains the regulatory step, why it matters and what it could mean for investors, the pharma sector and cross border deals in India.
In a significant ruling that could reshape how pharmaceutical companies protect their brand names, Bombay High Court has stepped in to support Sun Pharmaceutical Industries Ltd. in a high stakes trademark dispute, case revolves around two similar sounding drug brands: RACIRAFT (owned by Sun Pharma) and ESIRAFT (used by Ahmedabad based Meghmani Lifesciences Ltd.).
Read MoreIn a development that could rewrite the playbook for Indian pharmaceutical companies on the global stage, Sun Pharmaceutical Industries is reportedly preparing a binding all cash offer of around $12 billion to acquire U.S. based Organon & Co.
Read More
